Intrexon (XON) on Watch as FDA Green Lights GM Mosquitoes
- Nasdaq, S&P 500 slide at open as focus shifts to Fed
- BOJ hikes interest rates for first time in 17 years, to remain accommodative
- Buy the dip in US stocks in case of a 'rate shock' - Goldman
- World shares dip, yen slides amid landmark BOJ policy shift
- Nvidia unveils Blackwell, AI chip 'to power this new industrial revolution'
- Canoo Inc. (GOEV) Provides Update on $62M Share Pre-Paid Advance Agreement
- Super Micro Computer (SMCI) Announces Proposed 2M Share Offering
- StoneCo (STNE) Tops Q4 EPS by 33c
- JOANN Inc (JOAN) Enters Agreement to Reduce Debt and Receive $132 Mln in New Capital
- Cisco Systems (CSCO) Completes Acquisition of Splunk (SPLK)
Intrexon (XON)/Oxitec Announces FDA Finds No Significant Impact From Self-limiting Mosquito
August 5, 2016 10:43 AM EDTThe US Food and Drug Administration's Center for Veterinary Medicine (FDA-CVM) today published a final finding of no significant impact (FONSI) and final environmental assessment (EA) on Oxitec's self-limiting OX513A Aedes aegypti mosquito for an investigational trial in the Florida Keys. The finding concludes that a field trial of the Company's genetically engineered (GE) OX513A mosquitoes in Key Haven, Florida, will not result in a significant impact on the environment.
The publication of the final FONSI and EA follows an FDA-led evaluation of potential impacts on health and the environment of the proposed trial. This... More